Clinical Trial

Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cell therapy with or without rimegepant. The primary endpoint is complete response rate at 6 months after CAR-T cell infusion.
Trial Details
NCT Number NCT07613788
Lead Sponsor Ruijin Hospital
Conditions Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Enrollment 100 participants
Start Date 2026-05
Primary Completion 2028-11 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-29